Susceptibility of campylobacter pylori to macrolides and fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 22, Issue 5, 1988, Pages 631-636

  Hardy, Dwight J ^a   Hanson, Charles W ^a   Hensey, Dena M ^a   Beyer, Jill M ^a   Fernandes, Prabhavathi B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMPICILLIN; AZITHROMYCIN; BISMUTH NITRATE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DIFLOXACIN; DIRITHROMYCIN; ENOXACIN; ERYTHROMYCIN; ERYTHROMYCYLAMINE; FLUOROQUINOLONE DERIVATIVE; FLURITHROMYCIN; JOSAMYCIN; MACROLIDE; METRONIDAZOLE; MIOKAMYCIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; ROKITAMYCIN; ROXITHROMYCIN; SPIRAMYCIN; TEMAFLOXACIN; TOSUFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS, QUINOLONE; ANTIBIOTICS; CAMPYLOBACTER; MICROBIAL SENSITIVITY TESTS;

EID: 0024158757     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/22.5.631     Document Type: Article

References (23)

1. Bayerdörffer, E., Kasper, G., Pirlet, T., Sommer, A. & Ottenjann, R. (1987). Ofloxacin in der therapie Campylobacter-pylori-postUver ulcera duodem. Deutsche Medizinische Wochenschrift 112, 1407-11.
2. Coghlan, J. G., Humphries, H., Dooley, C., Keane, C., Gilligan, D., McKenna, D. et al. (1987). Campylobacter pylori and recurrence of duodenal ulcers-a 12-month follow-up study. Lancet it. 1109-11.
3. Czinn, S., Carr, H. & AronofT, S. (1986). Susceptibility of Campylobacter pylondts to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62, 993) and rifampin. Antimicrobial Agents and Chemotherapy 30, 328-9.
4. Fernandes, P. B. (1987). The macrolide revival: thirty five years after erythromycin. Antimicrobic Newsletter 4, 25-34.
5. Fernandes, P. B. & Chu, D. T. W. (1987). Quinolones. In Annual Reports in Medicinal Chemistry, Vol. 22 (Bailey, D. M., Ed.) pp.l 17-26. Academic Press, Orlando, FLA.
6. Fernandes, P. B., Hanson, C. W., Stamm, J. M., Vojtko, C., Shipkowitz, N. L. & St. Martin, E. (1987). The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo. Journal of Antimicrobial Chemotherapy 19, 449-65.
7. Glupczynski, Y., Labbe, M., Burette, A., Delmee, M., Avesani, V. & Bruck, C. (1987). Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet i, 1096.
8. Goodwin, C. S., Armstrong, J. A. & Marshall, B. J. (1986). Campylobacter pyloridis, gastritis, and peptic ulceration. Journal of Clinical Pathology 39, 353-65.
9. Goodwin, C. S., Blake, P. & Blincow, E. (1986) The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. Journal of Antimicrobial Chemotherapy 17, 309-14.
10. Lambert, T., Mégraud, F., Gerbaud, G. & Courvalin, P. (1986) Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrobial Agents and Chemotherapy 30, 510-1.
11. Langenberg, M. L„ Rauws, E A J., Schipper, M. E. I., Widjojokosumo, A., Tytgat, G. N. J., Rietra, P. J. G. M. et al. (1985). The pathogenic role of Campylobacter pyloridis studied by attempts to eliminate these organisms. In Campylobacter III: Proceedings of the Third International Workshop on Campylobacter Infections, Ottawa, 1985. (Pearson, A. D., Skirrow, M B., Lior, H. & Rowe, B., Eds), Abstract 098, pp. 162-3. Public Health Laboratory Service, London.
12. Marshall, B. (1983). Unidentified curved bacilli on gastric epithelium in active chronic gastritis Lancet i, 1273-5
13. Marshall, B., Armstrong, J A., McGechie, D. B. & Glancy, R. J. (1985). Attempt to fulfil Koch’s postulates for pylonc Campylobacter. Medical Journal of Australia 142, 436-9.
14. McNulty, C. A. M. (1987). The treatment of campylobacter-associated gastritis. American Journal of Gastroenterology 82, 245-7.
15. McNulty, C. A M, Dent, J. & Wise, R. (1985). Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrobial Agents Chemotherapy 28, 837-8.
16. McNulty, C. A. M., Gearty, J. C., Crump, B., Davis, M., Donovan, I. A., Melikian, V. etal.
17. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. British Medical Journal 293, 645-9.
18. Morgan, D. R, Freedman, R., Depew, C. E. & Kraft, W. G. (1987). Growth of Campylobacter pylori in liquid media. Journal of Clinical Microbiology 25, 2123-5.
19. National Committee for Clinical Laboratory Standards (1985). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A. National Committee for Clinical Laboratory Standards, Villanova, PA.
20. Shungu, D. L., Nairn, D. R., Gilman, R. H., Gadebusch, H. H., Cerami, A. T., Gill, C. etal.
21. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents. Antimicrobial Agents and Chemotherapy 31, 949-50.
22. Van Caekenberghe, D. L. & Breyssens, J. (1987). In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrobial Agents and Chemotherapy 31, 1429-30.
23. Warren, J. R., (1983). Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i, 1273.